ライフサイエンスコーパス: tyrosine kinase 2

1 concomitant phosphorylation of proline-rich tyrosine kinase 2.

2 activated the downstream kinase proline-rich tyrosine kinase 2.

3 ne phosphatase 1c with the receptor and with tyrosine kinase 2.

4 tein kinase C, Src kinases, and proline-rich tyrosine kinase 2.

5 of the receptor, STAT1, Janus kinase 1, and tyrosine kinase 2.

6 proteins were identified and include protein-tyrosine kinase 2 (also known as CAKbeta, RAFTK, and CAD

7 e kinase (RAFTK), also known as proline-rich tyrosine kinase 2 and cellular adhesion kinase beta, has

8 significant reduction of type I IFN-induced tyrosine kinase 2 and Jak1 phosphorylation.

9 ted in lung and accompanied by activation of tyrosine kinase 2 and STAT1.

10 Syk, focal adhesion kinase, and proline-rich tyrosine kinase 2, and in the absence of Dectin-1.

11 tyrosine phosphorylation of Janus kinase 2, tyrosine kinase 2, and STAT3 and STAT4 transcription fac

12 lzheimer's disease risk gene product protein tyrosine kinase 2 beta.

13 he phosphorylation and activation of protein-tyrosine kinase 2-beta (PTK2B, also referred to as Pyk2)

14 tein 9 (CARD9) disturb the subsequent spleen tyrosine kinase 2-CARD9/BCL10/MALT1-driven signaling cas

15 ocess: a phospholipase C/Ca(2+)/proline-rich tyrosine kinase 2/cJun N-terminal kinase pathway.

16 ntrolene-sensitive, nonreceptor proline-rich tyrosine kinase-2; components of the extracellular signa

17 ype 3 (ITPR3), and discoidin domain receptor tyrosine kinase 2 (DDR2).

18 atelets, including the adapter downstream of tyrosine kinase 2 (Dok-2).

19 dicted that the 86 amino acids following the tyrosine kinase 2 domain of beta PDGFR (amino acid resid

20 tyrosine phosphorylation of the proline-rich tyrosine kinase 2, epidermal growth factor receptor (EGF

21 AIMS: Drugs that inhibit the erb-b2 receptor tyrosine kinase 2 (ERBB2 or HER2) are the standard treat

22 Agents that inhibit the erb-b2 receptor tyrosine kinase 2 (ERBB2 or HER2), or vascular endotheli

23 the cell membrane, and that Erb-b2 receptor tyrosine kinase 2 (Erbb2) function is required for this

24 In a mouse model of basal ErbB2 receptor tyrosine kinase 2 (ErbB2)-positive breast cancer (ErbB2(

25 mRNA expression of discoidin domain receptor tyrosine kinase 2, fibronectin, and alpha-smooth muscle

26 e with a 2538 G-->A missense mutation in the tyrosine kinase-2 gene (Tyk2) are susceptible to Toxopla

27 r protein-tyrosine kinase Pyk2 (proline-rich tyrosine kinase 2) has been shown previously to regulate

28 Inhibition of proline-rich tyrosine kinase 2 improved insulin-induced and shear str

29 the tyrosine phosphorylation of proline-rich tyrosine kinase 2 in acinar cells.

30 tein kinase C, Src kinases, and proline-rich tyrosine kinase 2 in the process.

31 Proline-rich tyrosine kinase 2, in turn, caused activation of the MAP

32 ata further suggest that within this complex tyrosine kinase 2 is the tyrosine kinase responsible for

33 ACK2 (activated Cdc42-associated tyrosine kinase-2) is a nonreceptor tyrosine kinase that

34 Janus tyrosine kinase 2 (JAK2) is essential for signaling by t

35 with the BCR-ABL fusion kinase and the Janus tyrosine kinase 2 (JAK2) V617F mutation, respectively.

36 As the Janus tyrosine kinase 2 (Jak2)/signal transducer and activator

37 ion of JAKs, all JAKs (JAK1, JAK2, JAK3, and tyrosine kinase 2), JAK2, or JAK3, caused a significant

38 ty, including focal adhesion kinase, protein tyrosine kinase-2, Janus kinase, other focal adhesion-as

39 20-fold or greater selectivity over JAK2 and Tyrosine kinase 2 kinases.

40 Lemur tyrosine kinase 2 (LMTK2) is a transmembrane protein wit

41 ion study identified the gene encoding lemur tyrosine kinase-2 (LMTK2) as a susceptibility gene for p

42 in kinase C delta and , but not proline-rich tyrosine kinase 2, mediate tumor necrosis factor alpha-i

43 Context ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomark

44 r necrosis factor-alpha-induced proline-rich tyrosine kinase 2 phosphorylation, but at different tyro

45 Because tyrosine kinase 2 plays a role in differentiation of Th

46 iR-495 is positively associated with protein tyrosine kinase 2 (PTK2) in both groups.

47 CH patients with higher pretreatment protein tyrosine kinase 2 (PTK2) messenger RNA levels derived gr

48 sion of one such gene, that encoding protein tyrosine kinase 2 (ptk2, also known as focal adhesion ki

49 ion kinase [FAK] family members proline-rich tyrosine kinase 2 [Pyk-2] and FAK) was also examined usi

50 Proline-rich tyrosine kinase 2 (pyk2) activity is enhanced under thes

51 as mediated by FA formation and proline-rich tyrosine kinase 2 (PYK2) activity.

52 focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2) and also reduces the associatio

53 focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2) and their increased association

54 cells, phosphorylation of a FAK/proline-rich tyrosine kinase 2 (PYK2) consensus site in the alpha-hel

55 eceptor tyrosine kinase proline-rich protein tyrosine kinase 2 (Pyk2) functions as an integrator of m

56 tes the role of the nonreceptor proline-rich tyrosine kinase 2 (PYK2) in Ang II-induced VSMC protein

57 Despite the involvement of proline-rich tyrosine kinase 2 (Pyk2) in endothelial cell angiogenic

58 Proline-rich tyrosine kinase 2 (Pyk2) is a cytoplasmic tyrosine kinas

59 Proline-rich tyrosine kinase 2 (PYK2) is a cytoplasmic, non-receptor

60 Proline-rich tyrosine kinase 2 (Pyk2) is a member of the focal adhesi

61 Proline-rich tyrosine kinase 2 (Pyk2) is a member of the focal adhesi

62 Proline-rich tyrosine kinase 2 (Pyk2) is a novel cytosolic tyrosine k

63 in vitro studies indicated that proline-rich tyrosine kinase 2 (PYK2) is a positive mediator of osteo

64 Proline-rich tyrosine kinase 2 (Pyk2) is activated by various agonist

65 , expression of the FAK-related proline-rich tyrosine kinase 2 (Pyk2) is elevated and phosphorylated

66 Protein tyrosine kinase 2 (Pyk2) is required for T cell adhesion

67 study in this issue shows that proline-rich tyrosine kinase 2 (Pyk2) is responsible for acid-induced

68 Proline-rich tyrosine kinase 2 (PYK2) is the main adhesion-induced ki

69 FAK and its homolog Proline-rich tyrosine kinase 2 (Pyk2) modulate paxillin activation; h

70 l that tyrosine kinases Src and proline-rich tyrosine kinase 2 (Pyk2) regulate SHP-1-dependent LPS-in

71 The proline-rich tyrosine kinase 2 (Pyk2) was first identified as a key k

72 Previous findings suggest that protein-tyrosine kinase 2 (PYK2), a cytoplasmic kinase related t

73 Proline-rich tyrosine kinase 2 (PYK2), a major cell adhesion-activate

74 Proline-rich tyrosine kinase 2 (PYK2), a redox-sensitive tyrosine kin

75 Proline-rich tyrosine kinase 2 (PYK2), a tyrosine kinase structurally

76 Proline-rich tyrosine kinase 2 (PYK2), also known as cell adhesion ki

77 Proline-rich tyrosine kinase 2 (PYK2), also known as cellular adhesio

78 n focal tyrosine kinase (RAFTK)/proline-rich tyrosine kinase 2 (PYK2), an upstream effector of JNK an

79 yrosine-protein kinase) and the proline-rich tyrosine kinase 2 (Pyk2), and they can also cause robust

80 The FAK-related kinase, proline-rich tyrosine kinase 2 (Pyk2), is expressed in FAK(-/-) cells

81 ns of FAK are shared by its homolog, protein tyrosine kinase 2 (Pyk2), raising the question as to whe

82 vel substrate and interactor of proline-rich tyrosine kinase 2 (Pyk2).

83 rimary response gene-88 (MYD88)/proline-rich tyrosine kinase 2 (PYK2)/LYN complexes, which allows rec

84 the TLR4 cascade from activation of protein tyrosine kinase 2 (PYK2; also known as PTK2B).

85 egulated focal adhesion protein proline-rich tyrosine kinase-2 (Pyk2) and the effector proteins paxil

86 Here we demonstrate that proline-rich tyrosine kinase-2 (PYK2) deficiency impairs CD8 T-cell a

87 hosphorylation (Tyr-402) of the proline-rich tyrosine kinase-2 (PYK2) without significant change in a

88 al adhesion kinase (FAK) and/or proline-rich tyrosine kinase-2 (Pyk2), based on two lines of evidence

89 kinase Cs (aPKCs) by activating proline-rich tyrosine kinase-2 (PYK2), ERK pathway components, and ph

90 inhibitable; (b) dependent upon proline-rich tyrosine kinase-2 (PYK2), GRB2, SOS, RAS, RAF, and MEK1;

91 Inhibition of proline-rich tyrosine kinase 2 restores insulin-induced and shear str

92 cules downstream of the IFN receptor, namely tyrosine kinase 2, STAT1, and IFN regulatory factor 7, a

93 transcription (STAT) family, including JAK1, tyrosine kinase 2, STAT2, and STAT4 in the human progeni

94 that in cells expressing RAFTK/proline-rich tyrosine kinase 2, such as endothelial and B cells, RAFT

95 Y657 of eNOS and expression of proline-rich tyrosine kinase 2 that phosphorylates this residue were

96 G protein and to PLC-gamma via a downstream tyrosine kinase; 2) the initial AT1 receptor-PLC-beta1 c

97 NG-2 binds the endothelial-specific receptor tyrosine kinase 2 (TIE2) and acts as a negative regulato

98 ion of the angiopoietin receptor endothelial tyrosine kinase 2 (Tie2) or both angiopoietin-1 and angi

99 -specific tunica intima endothelial receptor tyrosine kinase 2 (Tie2) receptor kinase, angiopoietin-1

100 rotective tunica intima endothelial receptor tyrosine kinase 2 (Tie2).

101 necrosis factor-alpha activates proline-rich tyrosine kinase 2 to cause cytoskeletal disorganization

102 t-Aldrich syndrome protein, nor proline rich tyrosine kinase-2 to the target cell contact site.

103 ive (CYT387), which inhibits JAK1, JAK2, and tyrosine kinase 2 (TYK2) at low nanomolar concentrations

104 We report here that novel Tyrosine kinase 2 (Tyk2) gene mutations are present in v

105 cule inhibitor with specificity for JAK1 and tyrosine kinase 2 (TYK2) over other JAK family members.

106 mily of cytoplasmic tyrosine kinases) family tyrosine kinase 2 (TYK2) participates in signaling throu

107 cure, but we demonstrate that IL-22 acts via tyrosine kinase 2 (Tyk2), a member of the Jak family.

108 xis, connecting genetic aberrations in FLT3, tyrosine kinase 2 (TYK2), platelet-derived growth factor

109 the pseudokinase domain of the Janus kinase tyrosine kinase 2 (Tyk2), resulting in blockade of recep

110 el tyrosine kinase that phosphorylates Cx43, tyrosine kinase 2 (Tyk2).

111 for interferon (IFN)-regulated pathways and tyrosine kinase 2 (TYK2).

112 of phosphorylated Janus kinase 1 (JAK1) and tyrosine kinase 2 (Tyk2).

113 Concomitantly, IFN-alpha stimulation of tyrosine kinase 2 tyrosine phosphorylation and kinase ac

114 tein kinase C delta and mediate proline-rich tyrosine kinase 2 tyrosine phosphorylation.

115 t al. now show that mutation of another Jak, tyrosine kinase 2, underlies another human immunodeficie

116 small interfering RNA targeting proline-rich tyrosine kinase-2, which was also phosphorylated in resp